Improvement of insulin sensitivity in obese Zucker rats by myricetin extracted from Abelmoschus moschatus.
In an attempt to develop new substances for treating insulin resistance, obese Zucker rats were employed to screen the effect of myricetin, an active principle of Abelmoschus moschatus (Malvaceae), on insulin resistance. Myricetin purified from the aerial portion of the plant was administered intravenously ( I. V.) into animals. A dose-dependent decrease in the plasma glucose concentration of obese Zucker rats was observed 30 min following an I. V. injection. Moreover, repeated I. V. injection of myricetin (1 mg/kg) into obese Zucker rats 3 times daily for 1 week reduced the value of the glucose-insulin index, an index of insulin resistance calculated from the areas under the curve of glucose and insulin during the intraperitoneal glucose tolerance test. Additionally, repeated myricetin treatments overturned the inability of insulin to increase the expression of glucose transporter subtype 4 (GLUT 4) and to increase the protein levels and phosphorylation of insulin receptor substrate-1 (IRS-1) in soleus muscle of these obese rats. The inability of insulin to increase expression of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3-kinase) and to promote Akt serine phosphorylation in soleus muscle of these rats were also overturned by repeated myricetin treatments. These findings indicate that myricetin improves insulin sensitivity through increased post-receptor insulin signaling mediated by enhancements in IRS-1-associated PI3-kinase and GLUT 4 activity in muscles of obese Zucker rats. Myricetin might be used as a model substance for the development of antidiabetic compounds.
Liu
I-Min
IM
Department of Pharmacy, Tajen University, Yanpu Shiang, Ping Tung Shien, Taiwan, ROC. iml@mail.tajen.edu.tw
Tzeng
Thing-Fong
TF
Liou
Shorong-Shii
SS
Lan
Ting-Wei
TW
D028483:Abelmoschus; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D003920:Diabetes Mellitus / Q000188:drug therapy; D005419:Flavonoids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007333:Insulin Resistance; D009765:Obesity; D008517:Phytotherapy; D051381:Rats; D011924:Rats, Zucker
D001786:Blood Glucose; D005419:Flavonoids; D007004:Hypoglycemic Agents; C040015:myricetin